Bluebird bio’s stock $BLUE jumped over 20% on Thursday following its first-quarter earnings release and the announcement of 15 patients starting on its three approved gene therapies: Zynteglo, Skysona and Lyfgenia.
The company wrote in its financial report that 15 patients had completed starts on its expensive gene therapies: 11 on Zynteglo for transfusion-dependent thalassemia, three on Skysona for cerebral adrenoleukodystrophy and one on Lyfgenia for sickle cell. Bluebird expects 85 to 105 total patient starts across its portfolio this year.
Zynteglo costs $2.8 million per treatment, Lyfgenia $3.1 million and Skysona $3 million.
The company considers a “start” on a gene therapy as a patient’s first completion of a cell collection.
“We believe that once a patient goes through that process, that it’s highly likely that they’ll go through the entire journey and ultimately get treated and infused at the end of the day,” bluebird chief commercial and operating officer Tom Klima said on an investor call Thursday morning.
Klima added that he expects the number of starts to ramp up in the final two quarters of the year, with bluebird’s field team now focused on supporting qualified treatment centers that offer the company’s gene therapies. The company also expects to recognize revenue from its first infusion of Lyfgenia in the third quarter of this year.
Bluebird CEO Andrew Obenshain added on the call that the company will remain entirely focused on the US for the “near and probably midterm future.”
The company shuttered its commercial operations in Europe in 2021 after Germany and others refused to reimburse for Zynteglo at the price requested by bluebird.
“We are watching the ex-US geographies,” Obenshain said. “If we go there, we most likely go with a partner and not do it alone.”
Total revenue for the company hit $18.6 million for the first quarter of 2024, compared to $2.4 million in the same period in 2023, with the increase of $16.2 million due to Zynteglo revenue, the company said.
But the company noted discussions are “ongoing” with Medicaid agencies that represent 80% of Medicaid-insured Americans with sickle cell disease.
https://endpts.com/bluebird-bio-starts-15-patients-on-its-three-multi-million-dollar-gene-therapies/
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Exploring Tau Protein’s Role in Glaucoma: New Insights and Therapeutic Potential
Glaucoma, a chronic neurodegenerative disorder, leads to irreversible vision loss by damaging retinal ganglion cells (RGCs) and the optic nerve, often associated with increased intraocular pressure (IOP). Despite the benefits of IOP-lowering treatments, the underlying...
FDA-mandated CAR-T monitoring period could be halved, say researchers
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study...
Ancestral CRISPR-Cas13 Ribonucleases Discovered: Implications for Genome Editing
In a pioneering study published in *Science*, a team of researchers led by Peter H. Yoon and Jennifer A. Doudna from the University of California, Berkeley, has made a remarkable discovery in the realm of CRISPR technology. The team has identified an ancestral clade...
KBI Biopharma Expands Manufacturing Contract with Global Pharmaceutical Company
KBI Biopharma Inc., a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed...
Related Services
Plasmids GMP Services
AAV GMP Services
